340B Reform: What Hospital Leaders Should Consider for 2027

The 340B Drug Pricing Program, established to help hospitals and health systems stretch limited resources, allows eligible providers to purchase outpatient drugs at discounted prices and reinvest the savings into care for low-income and underserved populations. Over time, the program has become an important financial lever for many organizations.

However, as federal scrutiny of the 340B Drug Pricing Program intensifies, hospital executives should assume that 2027 may bring tighter oversight, more detailed reporting expectations, and additional pressure to demonstrate how 340B savings support their low-income and underserved patients.

U.S. Senator Bill Cassidy of Louisiana recently released a draft reform framework that would require hospitals to disclose how many patients receive 340B drugs, whether those patients are considered low income, and how savings are used for those patients, reflecting a policy shift toward greater transparency and accountability.

In parallel, the Health Resources and Services Administration (HRSA) is reconsidering implementation of a 340B Rebate Model Pilot Program, signaling continued momentum toward rebate-based mechanics and more prescriptive data submission requirements for covered entities.

For hospital and health system leaders, the strategic issue appears to be broader than pharmacy compliance alone. If rebate models expand or Congress adopts new reform provisions, hospitals and health systems participating in the program could face changes in cash-flow timing, contract pharmacy economics, internal reporting burdens, and external expectations regarding community benefit and reinvestment of program savings.

Hospitals that rely heavily on 340B-related margin to subsidize service lines, offset uncompensated care, or support physician alignment strategies should begin scenario planning now, rather than waiting for final rulemaking or legislation that could impact their 2027 budgets.

Items for consideration include:

1. Quantify the enterprise-wide financial contribution of 340B by hospital, clinic, contract pharmacy, drug class, and service line so leadership can model downside exposure under rebate-based purchasing or narrower contract pharmacy economics.
2. Strengthen governance by documenting how 340B savings are reinvested in charity care, access expansion, behavioral health, rural services, or other mission-driven initiatives that can be clearly defended to boards, regulators, and policymakers.
3. Review the integrity of the underlying data infrastructure, including claims capture, duplicate-discount controls, Medicaid billing logic, and pharmacy-revenue-cycle interfaces – because future oversight is likely to depend on claim-level accuracy and timely reporting.
4. Stress test service lines and physician arrangements that may depend, directly or indirectly, on 340B-supported margin. Drug-intensive specialties, ambulatory growth strategies, and certain employed-physician compensation structures may become harder to sustain if spreads compress or if reporting requirements materially increase administrative cost.

MMG can support hospital executives through service-line profitability analysis, physician compensation impact assessments and operational reviews of revenue cycle data workflows. By helping leadership teams connect 340B reform risk to enterprise finance and physician alignment, MMG can position clients to protect both operations and margin as 2027 approaches.

Ronnen Isakov is Managing Director Advisory Service of Management Group, LLC. His background includes extensive work in areas including business advisory, valuation, network optimization, transaction support, and project management.